Kane Biotech Inc. announced that it has entered into a worldwide license agreement with I-MED Pharma Inc. for the DispersinB® technology. Biofilm is a known contributor to Meibomian gland dysfunction (MGD) and dry eye blepharitis syndrome (DEBS). The DispersinB® enzyme will be used to enhance I-MED's line of eye care products.

The license agreement covers a period of five years and includes minimum annual royalties, which will start in 2025.